(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026735 A2

(51) International Patent Classification[7]: G01N 33/68

(21) International Application Number:
PCT/EP2004/010780

(22) International Filing Date:
20 September 2004 (20.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03090307.4	18 September 2003 (18.09.2003)	EP
60/512,078	20 October 2003 (20.10.2003)	US

(71) Applicant *(for all designated States except US)*: **EUROPROTEOME AG** [DE/DE]; Neuendorfstrasse 24 b, 16761 Hennigsdorf (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BUSCHMANN, Thomas** [DE/DE]; Spechtstrasse 5, 14612 Falkensee (DE). **FOTIADIS, Nikoleta-Kyriaki** [GR/DE]; Bornemannstrasse 6, 13357 Berlin (DE). **FUCHS, Miriam** [DE/DE]; Hermannstrasse 29, 14163 Berlin (DE). **HEIM, Steffen** [DE/DE]; Dunckerstrasse 29, 10439 Berlin (DE). **ILYNIA, Tatiana** [RU/DE]; Goethestrasse 7, 17489 Greifswald (DE). **LAMER, Stephanie** [DE/DE]; Schillerstrasse 25, 13158 Berlin (DE). **MEUER, Jörn** [DE/DE]; Hallandstrasse 12, 13183 Berlin (DE). **ROTHMANN-COSIC, Kirsten** [DE/DE]; Kronenstrasse 70, 10177 Berlin (DE). **SEIBERT, Volker** [DE/DE]; Schulzestrasse 7, 13187 Berlin (DE). **PÉREZ, Silvia, Tortola** [ES/DE]; Schwedenstrasse 13, 13357 Berlin (DE).

(74) Agents: **GULDE, Klaus W.** et al.; Anwaltskanzlei, Gulde Hengelhaupt Ziebig & Schneider, Wallstrasse 58/59, 10179 Berlin (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/026735 A2

(54) Title: DIFFERENTIALLY EXPRESSED TUMOUR-SPECIFIC POLYPEPTIDES FOR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER

(57) Abstract: The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide binding protein beta 2-like 1 (GNB2L1), guanine nucleotide binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low density lipoprotein receptor-related protein 4 (LRP4), human glomerular epithelial protein 1 (GLEPP1), toll-like receptor 3 (TLR3), and/or zona pellucida glycoprotein 3A (ZP3) for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and/or biological activity of said proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and/or biological activity of said proteins including using agents identified in screening assays described herein, vector delivery of antisense polynucleotide sequences, and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin.